Clinical trial
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or…
NCT00084513 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00084513 |
|---|---|
| Title | Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer |
| Official title | Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, imatinib mesylate |
| Enrollment | 18 |
| Start date | Aug 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Jun 11, 2004 |
| Last update posted | Feb 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: